The Medical Cannabis Beverage Product Amendment Act of 2026 introduces a new framework for the production and regulation of medical cannabis beverages in the District of Columbia. It allows holders of class A or B alcohol manufacturer licenses to produce medical cannabis beverages in collaboration with licensed medical cannabis manufacturers, provided that these beverages do not contain alcohol. The bill also establishes a medical cannabinoids import endorsement, enabling the importation of non-intoxicating cannabinoids into the District. Furthermore, it expands the role of licensed medical cannabis couriers to facilitate the delivery of cannabis products between licensed businesses and clarifies tax regulations, imposing a 6% tax on gross receipts from medical cannabis sales.

The legislation amends Title 25 of the D.C. Official Code to incorporate these new provisions, ensuring compliance with safety and regulatory standards through strict testing and tracking requirements. It also revises the Legalization of Marijuana for Medical Treatment Initiative of 1999 to define key terms related to cannabinoids and medical cannabis beverages. Additionally, the bill sets a $500 fee for the new medical cannabis beverage production endorsement and a $1,000 annual fee for the import endorsement, with tax revenues initially directed to the Healthy DC and Health Care Expansion Fund before being allocated to the District's General Fund in subsequent years.